3 New Strong Buy Ratings from Top-Rated Analysts: 04/03/2026
Here’s a peek at the latest picks from our Strong Buy Stocks from Top Wall Street Analysts screener:
- Tenet Healthcare (THC) — 15 analysts agree: this healthcare giant is a Strong Buy
- Nature's Sunshine Products (NATR) — Record-breaking results from the #1 Zen Rated stock
- AnaptysBio (ANAB) — Major spin-off and $100M buyback fuel analyst excitement
P.S. Want more trending tickers? Check out our latest video about quantum stocks poised to explode.
A note from our sponsors...
The AI That Could Triple Your Money This Year
Early users could have already tripled their money every single year this AI has been live, based on the average winning trade spotted - WITHOUT having to check the news, WITHOUT watching the Fed, and WITHOUT all the stress most traders have to deal with. For now, you can try this AI yourself, completely free of charge - no email, no credit card.
1. Tenet Healthcare Corp (NYSE: THC)
With earnings momentum building ahead of its May 5th report, diversified healthcare player THC is turning heads on Wall Street as one of the highest-rated stocks in the A-rated Medical Care Facility industry.
Zen Rating: Strong Buy (A) — see full analysis
Recent Price: $188.71 — get current quote
Max 1-year forecast: $288.00
Why we're watching:
- Analyst support: THC commands strong Street backing among the analysts we track, with 12 Strong Buy and 3 Buy ratings from 15 analysts. See the ratings
- Truist Securities' David S Macdonald (a top 11% rated analyst) maintains his Strong Buy rating following meetings with management, emphasizing the company's strong fundamentals and positive growth prospects in the healthcare sector.
- UBS analyst A.J. Rice (top 12%) continues to highlight the company's strong demand for healthcare services and expansion plans in underserved markets, supporting the bullish thesis.
- Industry ranking context: THC is currently the 6th highest-rated stock out of 39 in the Medical Care Facility industry, which has an Industry Rating of A.
- Zen Rating highlights: As a Strong Buy (A) rated stock, THC ranks in the top 5% of stocks we track — a category that has historically delivered 32.52% annual returns.
- Component Grades: The stock earns particularly strong marks for Value and Sentiment, with solid Financials and Momentum scores reflecting both fundamental strength and market enthusiasm. (See all 7 Zen Component Grades here)
2. AnaptysBio Inc (NASDAQ: ANAB)
With the First Tracks Biotherapeutics spin-off set for April 20th and a freshly authorized $100 million stock repurchase plan, this biotech company is entering a transformative stretch that has Wall Street paying close attention.
Zen Rating: Buy (B) — see full analysis
Recent Price: $55.81 — get current quote
Max 1-year forecast: $100.00
Why we're watching:
- Analyst support: ANAB commands strong backing with 5 Strong Buy and 2 Buy ratings from 7 covering analysts. See the ratings
- For instance, Barclays analyst Etzer Darout (a top 2% rated analyst) maintains his Strong Buy rating with a $79 price target (40%+ upside), believing that AnaptysBio's innovative approaches will drive success in an evolving market, emphasizing that competitive advantages are growing.
- Guggenheim's Yatin Suneja (top 3%) sets the Street-high $100 price target (+80.54% upside), with insights suggesting a bullish future based on data from recent trials showing that innovations are driving growth and data supports potential market share gains.
- Industry ranking context: ANAB is currently the 13th highest-rated stock in the Biotech industry. See all biotech stocks here.
- Zen Rating highlights: ANAB currently earns a Zen Rating of B (Buy), which means it ranks in the top 20% of stocks we track based on a careful 115-factor review. Considering the volatility of the biotech industry, this is pretty impressive.
- Component Grades: ANAB demonstrates balanced strength with a Momentum grade of B and Sentiment grade of B, though the Safety grade of F reflects the typical risk profile of clinical-stage biotech companies, while Financials earn a B grade supported by a strong 45.8% profit margin. (See all 7 Zen Component Grades here)
3. Natures Sunshine Products (NASDAQ: NATR)
Despite operating in a challenging D-rated Food industry, natural food and wellness company NATR shines as the 2nd highest-rated stock in the sector — backed by record-breaking results and unanimous Strong Buy ratings from covering analysts.
Zen Rating: Strong Buy (A) — see full analysis
Recent Price: $23.94 — get current quote
Max 1-year forecast: $33.00
Why we're watching:
- Analyst support: NATR enjoys unanimous support and Strong Buy ratings among the analysts we track issuing ratings. See the ratings
- For example, Canaccord Genuity's Susan Anderson (a top 13% rated analyst) maintains her Strong Buy rating and projected 37% upside price target, highlighting NATR's potential to outperform the industry due to its unique positioning and branding strategy, with strategic partnerships expected to enhance distribution.
- NATR is a valued addition to our Zen Investor portfolio, where Editor-in-Chief Steve Reitmeister rates the stock a Buy and praises its solid fundamentals and excellent historical track record.
- The company's earnings report beat revenue estimates by 7.76% with year-over-year revenue growth of 7.76%, while management remains optimistic about upcoming trends in health and wellness that may favor their product line.
- Industry ranking context: NATR is currently the 2nd highest-rated stock in the Food industry, though as previously noted, the industry is not well-rated. (Here’s why Industry Ranking matters.)
- Zen Rating highlights: NATR ranks in the top 1% of stocks we track based on fundamentals — a fact that shouldn’t be ignored despite the ailing industry. Its overall rating is A (Strong Buy).
- Component Grades: Sentiment earns an excellent A grade, while Value and Financials earn above-average Bs. (See all 7 Zen Component Grades here)
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.